Intensity Therapeutics, Inc. announced on March 27 its financial results for the year ended December 31, 2025, along with key updates on its clinical programs and corporate activities.
The company’s announcement is significant as it highlights progress in cancer drug development, ongoing clinical trials, and recent fundraising efforts that extend its operational runway into the second quarter of 2027. These developments are relevant to patients with hard-to-treat cancers and to stakeholders monitoring advances in oncology.
In its update, Intensity Therapeutics reported continued work on two major studies: the INVINCIBLE-4 Phase 2 study for triple negative breast cancer and the INVINCIBLE-3 Phase 3 trial for soft tissue sarcoma. While new patient enrollment in INVINCIBLE-3 was paused in March 2025 due to funding constraints after enrolling 21 patients, the company said it continues treating current participants and plans to resume enrollment once additional funding is secured. The company also highlighted a publication of data from its IT-01 phase 1/2 study in eBioMedicine, a Lancet Discovery Science journal.
Financially, Intensity raised over $20 million through public offerings during the year. As of December 31, cash and cash equivalents totaled $11.9 million. Research and development expenses decreased to $6.8 million from $10.5 million in the prior year due mainly to lower costs associated with pausing new site activations for INVINCIBLE-3; general and administrative expenses were also reduced by nearly $1 million compared to last year.
Founder, President, and CEO Lewis H. Bender said: “Our data published in the Lancet’s eBioMedicine journal for the treatment of metastatic disease, and the results reported on the safety and efficacy in the INVINCIBLE-4 study were promising and unique for a locally-delivered oncology drug. With the capital raised in 2025 and an unused $60 million ATM facility in place, we intend to resume patient enrollment in both studies as soon as possible… The ACS data supports the conclusion that today’s cancer treatments have many limitations, and that the unmet medical need for new ideas and better cancer therapies remains as strong as ever.”
PR Newswire operates globally across more than 170 countries with support available in over 40 languages according to their official website. Their network delivers global reach for press release distribution through collaborations with over half a million media outlets worldwide according to PR Newswire. They offer services such as AI-enhanced content tools alongside traditional press release distribution as outlined by PR Newswire, supported by expert editors providing round-the-clock assistance according to PR Newswire.
Looking ahead, Intensity Therapeutics aims to restart paused clinical activities pending additional funding while maintaining focus on developing INT230-6—its lead investigational product designed for direct tumor injection—and continuing research into novel approaches intended to improve outcomes for patients facing difficult cancers.
